Arch Biopartners Inc.
ARCH.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -61.57% | 67.73% | -- | -13.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -61.57% | 67.73% | -- | -13.43% |
| Cost of Revenue | -95.56% | -41.51% | 120.92% | 48.43% | -12.93% |
| Gross Profit | 78.28% | -88.14% | -200.70% | -136.30% | 10.95% |
| SG&A Expenses | -19.62% | -67.90% | 23.08% | 6.26% | 128.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -85.05% | -63.34% | 139.55% | 29.31% | -4.77% |
| Operating Income | 52.46% | 64.12% | -290.51% | -62.30% | -21.78% |
| Income Before Tax | 48.94% | 48.34% | -544.48% | -92.61% | -19.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 48.94% | 48.34% | -544.48% | -92.61% | -19.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.94% | 48.34% | -544.48% | -92.61% | -19.72% |
| EBIT | 52.46% | 64.12% | -290.51% | -62.30% | -21.78% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 51.47% | 50.00% | -558.62% | -90.74% | -18.26% |
| Normalized Basic EPS | 50.59% | 50.00% | -561.11% | -88.24% | -18.06% |
| EPS Diluted | 51.47% | 50.00% | -558.62% | -90.74% | -18.26% |
| Normalized Diluted EPS | 50.59% | 50.00% | -561.11% | -88.24% | -18.06% |
| Average Basic Shares Outstanding | 4.32% | 3.96% | -2.92% | 0.47% | 1.11% |
| Average Diluted Shares Outstanding | 4.32% | 3.96% | -2.92% | 0.47% | 1.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |